Back to News
Market Impact: 0.2
SPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class Action
Source: prnewswire.com
Legal & LitigationHealthcare & Biotech
A securities class action alleges that ARS Pharmaceuticals misrepresented the timing of expanded CVS Caremark coverage for neffy. Purchasers of SPRY securities retain rights to seek appointment as lead plaintiff or remain absent class members; the article provides no damages estimate, court ruling, or company response.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
CVS0.00
SPRY-0.80
More News
- Paraguay raids ex-president’s home: Why a bank crash brought down Pena
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Why is Nvidia’s Jensen Huang at the centre of a US-China spy scandal?
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion
- What Jensen Huang's affair with an accused Chinese spy means for Nvidia stock
- Nvidia stock falls 5% as scrutiny turns to Jensen Huang’s relationship with alleged Chinese spy